CRISPR Therapeutics stock edges lower as investors digest latest pipeline and earnings figures
Published on 09/20/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CRISPR Therapeutics AG stock (ISIN CH0334081137) is trading at about USD 56.56 as of September 20, 2026 on Nasdaq, roughly 1.33% below the prior close, underscoring how sensitive the shares remain to shifts in sentiment around gene-editing therapies.
Recent price performance and valuation context
According to an overview on September 20, 2026, CRISPR Therapeutics stock recently showed a daily move of minus 1.33% to USD 56.56, highlighting a modest pullback after earlier rallies in 2026. Over the latest 52-week period, the shares have oscillated between lows and highs that frame the current price level as mid-range within the yearly trading band, a typical pattern for high-beta biotech names where clinical and regulatory news can quickly re-rate valuations.
At the current quotation around USD 56.56, the implied market capitalization of CRISPR Therapeutics stands in the mid-single-digit billions of USD as of September 20, 2026, placing the company in the group of mid-cap biotechnology stocks where individual trial results and partnership announcements can materially shift expectations. For investors, the interaction between market cap and the pipeline’s potential revenue and profit contribution over the coming years is central to the risk-reward calculus.
Latest reported figures and pipeline signals
In the most recent reported quarter within the 2026 fiscal year, CRISPR Therapeutics disclosed revenue in the tens of millions of USD, tied primarily to collaboration and license agreements, while research and development expenses remained significantly higher, leading to a net loss for the period. The company’s earnings per share for that quarter were negative, consistent with its development-stage profile, and the loss widened versus the same quarter a year earlier as the pipeline advanced and clinical programs expanded.
Historically, CRISPR Therapeutics reported that full-year revenue in a prior fiscal year stood in the low hundreds of millions of USD, largely driven by one-time or milestone payments, with operating losses reflecting the heavy investment in gene-editing platforms and therapeutic candidates. In that earlier year, the company’s net loss per share also remained substantial, illustrating that profitability is still a medium-term goal rather than an immediate milestone and providing a baseline for investors comparing newer quarterly results in 2026 against past performance.
From a pipeline perspective, CRISPR Therapeutics’ clinical and preclinical programs across hematology, immunology and other indications have progressed through key checkpoints in 2026, adding data that can either de-risk future revenue potential or raise new questions. When quarterly figures show higher research spending in 2026 compared with the historical year, the quantified comparison between rising R&D and still-limited revenue underscores that the core investment thesis continues to hinge on future approval and commercialization rather than current earnings power.
Analyst expectations and risk factors
Analyst consensus data compiled in 2026 indicate that Wall Street continues to model negative EPS for CRISPR Therapeutics for the current fiscal year, followed by a less negative profile in the next year as revenue from collaborations and potential product launches is expected to increase. In those estimates, the current-year EPS is projected around minus mid-single digits in USD, with the following year improving by roughly one dollar per share, a quantified step that helps investors gauge how quickly the loss per share might narrow if pipeline progress continues.
At the same time, analyst models for long-term growth often assume double-digit percentage increases in revenue once key gene-editing programs reach the market, but those forecasts are subject to significant execution, safety and regulatory risks. Comparing the current negative EPS estimates for 2026 with the more optimistic positive EPS expectations further into the future highlights the tension between the near-term financial drag of R&D and the longer-term potential for high-margin therapies.
For investors, major risks remain concentrated in clinical trial outcomes, regulatory scrutiny of gene-editing, manufacturing scalability and competition from other advanced therapies. When quarterly reports show that cash burn has increased compared with the prior year while revenue remains modest, the numerical gap between operating cash outflows and inflows becomes a critical metric, especially if the company needs to raise additional capital that could dilute existing shareholders.
Stock level and investor takeaway
With CRISPR Therapeutics stock at about USD 56.56 on Nasdaq as of September 20, 2026, roughly 1.33% below the prior close and positioned near the middle of its 52-week trading range, the shares reflect a market that is balancing the promise of gene-editing against the reality of ongoing losses and execution risk. For investors, the next set of quarterly figures and pipeline updates will provide the most important checkpoints to reassess whether the current market capitalization aligns with the company’s progress.
CRISPR Therapeutics AG stock facts
- Company: CRISPR Therapeutics AG
- ISIN: CH0334081137
- Ticker: CRSP
- Trading venue: Nasdaq
- Price (as of September 20, 2026): 56.56 USD
- Market capitalization: mid-single-digit billions USD (as of September 20, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Nasdaq biotechnology universe
